Le Registre des lobbyistes
| Objets | Détails | Catégories |
|---|---|---|
|
Santé, Industrie
|
Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs
|
Politique ou Programme
|
|
Santé, Industrie
|
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
|
Politique ou Programme
|
|
Santé, Industrie
|
Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products
|
Proposition législative, Projet de loi ou résolution
|
|
Santé, Industrie
|
Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
|
Politique ou Programme
|
|
Environnement, Industrie
|
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
|
Règlement, Proposition législative, Projet de loi ou résolution
|
|
Santé, Industrie
|
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
|
Politique ou Programme
|
|
Santé, Industrie
|
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
|
Politique ou Programme
|
|
Santé, Industrie
|
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
|
Politique ou Programme
|
|
Santé, Industrie
|
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
|
Règlement
|
|
Santé, Industrie
|
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
|
Règlement, Proposition législative, Projet de loi ou résolution
|
|
Affaires étrangères, Santé, Industrie
|
Free trade treaty agreement as they relate to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership
|
Politique ou Programme
|
|
Santé, Industrie
|
Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
|
Règlement
|
|
Santé, Industrie
|
Health Canada’s Interim Orders relating to COVID-19: The Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19; The Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19; The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19; The Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to Covid-19
|
Proposition législative, Projet de loi ou résolution
|
|
Santé, Industrie
|
New Substances Notification Regulations as it relates to the biopharmaceutical industry
|
Règlement
|
|
Santé, Industrie
|
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
|
Proposition législative, Projet de loi ou résolution
|
|
Santé, Industrie, Propriété intellectuelle
|
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
|
Règlement
|
|
Santé, Industrie, Propriété intellectuelle
|
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
|
Règlement
|
|
Santé, Industrie, Propriété intellectuelle
|
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
|
Règlement
|
|
Santé, Industrie
|
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
|
Politique ou Programme
|
|
Santé, Industrie
|
Proposed pharmacare legislation related to any future national pharmacare program
|
Proposition législative, Projet de loi ou résolution
|
|
Santé, Industrie, Recherche et développement, Impôts et finances
|
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
|
Politique ou Programme
|
|
Santé, Industrie
|
Smart Regulations as it relates to the biopharmaceutical industry
|
Règlement
|
|
Santé, Industrie, Recherche et développement
|
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
|
Politique ou Programme
|
|
Santé, Industrie
|
The government's Science and Technology strategy as it relates to the biopharmaceutical industry
|
Politique ou Programme
|
|
Santé, Industrie
|
World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG) World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property
|
Politique ou Programme
|
|
Santé, Industrie
|
World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
|
Politique ou Programme
|
Adresse :
55 Metcalfe Street, Suite 1220
Ottawa, ON K1P 6L5
Canada
Numéro de téléphone :
613-236-0455
Adresse Web :
http://innovativemedicines.ca/
David Renwick, Interim President
Innovative Medicines Canada n'est pas une filiale d'une société mère.
Innovative Medicines Canada n'est pas une coalition.
Les activités de Innovative Medicines Canada ne sont pas contrôlées ou dirigées par une autre personne morale ou physique ou par une organisation, qui est directement intéressée au résultat de cet engagement.
Innovative Medicines Canada ne possède aucune filiale qui pourrait être directement intéressée au résultat de l'engagement
John Delacourt | Charges publiques occupées
Cabinet d'expert-conseil : Counsel Public Affairs